Various types of stem cells, including a population of very small embryonic-like stem cells, are mobilized into peripheral blood in patients with Crohnʼs disease

Marlicz, Wojciech; Zuba‐Surma, Ewa; Kucia, Magda; Błogowski, Wojciech; Starzyńska, Teresa; Ratajczak, Mariusz Z.

doi:10.1002/ibd.22875

Cited by 68 publications

(58 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared with those who are in remission, patients with active CD have higher level of CD105+/STRO-1+/CD45 cells, which are markers for MSCs in their peripheral blood, suggesting that active CD may stimulate MSC mobilization [24]. …”

Section: Mscs CD and Pharmacological Interactionmentioning

confidence: 99%

Mesenchymal Stromal Cell Therapy for Crohn's Disease

Liew

O’Brien

Egan

2014

Dig Dis

View full text Add to dashboard Cite

Current treatment approaches fail to address the underlying factors responsible for the pathogenesis of Crohn's disease (CD). Mesenchymal stromal cells (MSCs) are fibroblastic plastic adherent cells with specific surface markers, and may demonstrate trilineage differentiation ability. MSCs can be isolated from either the adipose tissue, bone marrow or umbilical cord. In refractory fistulizing CD, both autologous and allogeneic MSC therapy with repeated administrations is a feasible and safe therapeutic option with suggestion of efficacy, and several phase 3 trials are currently underway to determine its efficacy. In this review, we discuss the potential therapeutic role of MSC therapy for CD, which is predominantly related to its immunomodulatory role. The characteristics of MSCs derived from patients with CD and its pharmacological interaction are outlined. Preclinical studies using experimental models of colitis and clinical studies using MSCs for the treatment of fistulizing CD are highlighted. Finally, the current perspective and potential limitations of this novel therapy with recommendations for future studies are discussed.

show abstract

Section: Mscs CD and Pharmacological Interactionmentioning

confidence: 99%

Mesenchymal Stromal Cell Therapy for Crohn's Disease

Liew

O’Brien

Egan

2014

Dig Dis

View full text Add to dashboard Cite

show abstract

“…Previous studies investigating EPCs in the setting of CD have yielded conflicting results, and it is still unclear whether the absolute peripheral EPC number increases or decreases in the disease [7][8][9]. Previous studies are small and not adequately controlled for disease activity.…”

Section: Introductionmentioning

confidence: 96%

Circulating Bone Marrow-Derived CD45−/CD34+/CD133+/VEGF+ Endothelial Progenitor Cells in Adults with Crohn’s Disease

et al. 2016

View full text Add to dashboard Cite

show abstract

“…[63][64][65] The existence of these cells has recently been confirmed by several independent groups of investigators, and they have been postulated…”

mentioning

confidence: 99%

Stem cells and clinical practice: new advances and challenges at the time of emerging problems with induced pluripotent stem cell therapies

Ratajczak¹,

Bujko²,

Wojakowski³

2016

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

REVIEW ARTICLE Stem cell therapies 879retina, damaged liver, extensive skin burns, diabetes, and Parkinson disease. Unfortunately, beyond hematological applications, the results for other clinical applications of stem cells have been disappointing, and several encouraging results reported in laboratory animals have not been reproduced in humans.6 Overall, the promise of clinical applications of stem cells and their success have often been exaggerated by the news media.On the other hand, it is well known that stem cells residing in adult tissues are responsible for organ rejuvenation. However, this process occurs at a different pace in various tissues. While hematopoietic cells, intestinal epithelium, and epidermis are continuously replaced by new cells, this Introduction Stem cell therapies began 50 years ago with the first transplantation of hematopoietic stem cells to replace damaged hematopoietic systems. The successful application of these cells in the hematological setting encouraged attempts to employ them in treating several other clinical problems encountered in cardiology, orthopedics, neurology, diabetology, opthalmology, dermatology, and gastroenterology.1-5 Accordingly, stem cell-based therapeutic strategies have been proposed for treating a multitude of clinical problems, including damaged myocardium after heart infarction, damage to the brain after stroke, damaged spinal cord after mechanical injury, age-related macular degeneration of the REVIEW ARTICLE

show abstract

Various types of stem cells, including a population of very small embryonic-like stem cells, are mobilized into peripheral blood in patients with Crohnʼs disease

Abstract: CD triggers the mobilization of MSCs, EPCs, and VSELs, while the significance and precise role of these mobilized cells in repair of damaged intestine requires further study.

Cited by 68 publications

References 35 publications

Mesenchymal Stromal Cell Therapy for Crohn's Disease

Mesenchymal Stromal Cell Therapy for Crohn's Disease

Circulating Bone Marrow-Derived CD45−/CD34+/CD133+/VEGF+ Endothelial Progenitor Cells in Adults with Crohn’s Disease

Stem cells and clinical practice: new advances and challenges at the time of emerging problems with induced pluripotent stem cell therapies

Contact Info

Product

Resources

About